Levobunolol

Levobunolol (l-Bunolol) is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol is an ocular hypotensive agent and lowers mean intraocular pressure (IOP) . Levobunolol can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3].

Product Specifications

CAS Number

[47141-42-4]

Product Name Alternative

L-Bunolol

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/levobunolol.html

Solubility

10 mM in DMSO

Smiles

O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C

Molecular Formula

C17H25NO3

Molecular Weight

291.39

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Mohammadi M, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. Acta Biomater. 2018 Jun;73:90-102.|[2]Kumar, N, et al. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Futur J Pharm Sci 6, 109 (2020) .|[3]Zhang M, et al. Superior oblique myokymia treated with levobunolol. J AAPOS. 2018 Feb;22 (1) :67-69.e2.